News | Molecular Imaging | July 02, 2015

Mevion Medical Systems Delivers Proton Accelerator to Seidman Cancer Center at University Hospitals

Mevion S250 will be Ohio's first proton therapy system when operation begins in spring 2016

Mevion, S250, Seidman Cancer Center, University Hospitals, UH, proton therapy

July 2, 2015 - Mevion Medical Systems announced delivery of the superconducting synchrocyclotron accelerator for its Mevion S250 proton therapy system for installation at University Hospitals (UH) Seidman Cancer Center and UH Rainbow Babies & Children's Hospital in Cleveland.

The accelerator is the core of the proton therapy system, and its installation is a crucial step in the deployment of the system at UH. The unit will be the first proton therapy system in Ohio treating adult and pediatric cancer patients when it begins clinical operation in the spring of 2016. This is the sixth accelerator delivery for Mevion.

"We are extremely excited to bring this leading-edge proton beam facility to Ohio," said Nathan Levitan, M.D., president of UH Seidman Cancer Center. "As a national leader in cancer care, University Hospitals Seidman Cancer Center is committed to providing patients with the most advanced cancer-fighting technology and treatments. The addition of the Mevion S250 will be a great complement to our existing state-of-the-art radiation oncology equipment and expertise and will benefit patients with many different types of cancer. Additionally, it provides a distinct advantage to our pediatric patients and their families at UH Rainbow Babies & Children's Hospital, eliminating the need to travel out of state for this technology, which results in fewer long-term effects due to the precisely targeted therapy."

Proton therapy is an advanced form of radiation therapy that targets cancer cells more directly while sparing much of the surrounding healthy tissue, thus making it ideal for treating pediatric patients as well as adults with cancer in sensitive locations such as near the heart or brain. Traditional proton therapy systems cost hundreds of millions of dollars to build and are typically the size of a football field. However, the Mevion S250 provides precise, effective and efficient treatment without the complexity of traditional systems. In addition, the capital costs and the operating costs are significantly less as the Mevion S250 requires less space, less staff and less energy than other proton systems.

Following the installation of the accelerator, the system will undergo proton beam tuning and acceptance testing to verify that it meets precise technical and clinical requirements before being commissioned for clinical use. It is expected to begin treating cancer patients in the spring of 2016. 

Currently, three Mevion S250 proton therapy systems are in clinical operation treating patients.

For more information: www.mevion.com

Related Content

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Varian Acquiring Cancer Treatment Services International
News | Radiation Therapy | May 21, 2019
Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment...
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Radiation Therapy | May 10, 2019
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve